

Ref: FOI/2025/10502

Date Received: 5th February 2025

Response Due: 5th March 2025

Date: 21st February 2025

Dear Sir/Madam

With reference to your request for information received on 5th February 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- **Abatacept [Orencia]** = 19.
- **Adalimumab [Humira]** = 43.
- **Adalimumab Biosimilars** = 118.
- **Apremilast [Otezla]** = <5.
- **Baricitinib [Olumiant]** = 12.
- **Bimekizumab [Bimzelx]** = 6.
- **Certolizumab [Cimzia]** = 25.
- **Etanercept [Enbrel]** = 24.
- **Etanercept Biosimilars** = 166.
- **Filgotinib [Jyseleca]** = <5.
- **Golimumab [Simponi]** = 16.
- **Guselkumab [Tremfya]** = <5.
- **Infliximab [Remicade]** = <5.
- **Infliximab Biosimilars** = <5.
- **Ixekizumab [Taltz]** = <5.
- **Risankizumab [Skyrizi]** = 0.
- **Rituximab [MabThera]** = <5.
- **Rituximab Biosimilars** = 34.
- **Sarilumab [Kevzara]** = 0.
- **Secukinumab [Cosentyx]** = 53.

- Tocilizumab [Ro Actemra] = 77.
- Tocilizumab Biosimilars = 0.
- Tofacitinib [Xeljanz] = 5.
- Upadacitinib [Rinvoq] = 6.
- Ustekinumab [Stelara] = <5.
- Ustekinumab Biosimilar = 0.

2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:

- Abatacept [Orencia] = 0.
- Adalimumab [Humira] = 20.
- Adalimumab Biosimilars = 35.
- Apremilast [Otezla] = <5.
- Bimekizumab [Bimzelx] = 6.
- Certolizumab [Cimzia] = 5.
- Etanercept [Enbrel] = 12.
- Etanercept Biosimilars = 23.
- Golimumab [Simponi] = 9.
- Guselkumab [Tremfya] = <5.
- Infliximab [Remicade] = <5.
- Infliximab Biosimilars = 0.
- Ixekizumab [Taltz] = <5.
- Risankizumab [Skyrizi] = 0.
- Secukinumab [Cosentyx] = 22.
- Tofacitinib [Xeljanz] = <5.
- Upadacitinib [Rinvoq] = <5.
- Ustekinumab [Stelara] = <5.
- Ustekinumab Biosimilar = 0.

The Trust has a standard procedure of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

A handwritten signature in black ink that reads "Masterman". The signature is fluid and cursive, with a long horizontal stroke at the end.

Gary Masterman
Deputy Chief Pharmacist

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111